In the HIV-1 envelope cytoplasmic domain results in a loss ofIn the HIV-1 envelope cytoplasmic

In the HIV-1 envelope cytoplasmic domain results in a loss of
In the HIV-1 envelope cytoplasmic domain results in a loss of Env-mediated fusion and infectivity. Retrovirology 2011, 8:37. 9. Dimonte S, Mercurio F, Svicher V, D’Arrigo R, Perno CF, Ceccherini-Silberstein F: Selected amino acid mutations in HIV-1 B subtype gp41 are associated with specific gp120v(3) signatures in the regulation of co-receptor usage. Retrovirology 2011, 8:33.10. D’Souza MP, Mangafodipir (trisodium)MedChemExpress Mangafodipir (trisodium) Cairns JS, Plaeger SF: Current evidence and future directions for targeting HIV entry: therapeutic and prophylactic strategies. JAMA 2000, 284:215?22. 11. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD: Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007, 317:1930?934. 12. Daar ES, Li XL, Moudgil T, Ho DD: High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A 1990, 87:6574?578. 13. Schooley RT, Merigan TC, Gaut P, Hirsch MS, Holodniy M, Flynn T, Liu S, Byington RE, Henochowicz S, Gubish E: Recombinant soluble CD4 therapy in patients with the acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. A phase I-II escalating dosage trial. Ann Intern Med 1990, 112:247?53. 14. Haim H, Si Z, Madani N, Wang L, Courter JR, Princiotto A, Kassa A, PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/25447644 DeGrace M, Gee-Estrada K, Mefford M, Gabuzda D, Smith AB III, Sodroski J: Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state. PLoS Pathog 2009, 5:e1000360. 15. Jiang S, Lin K, Strick N, Neurath AR: HIV-1 inhibition by a peptide. Nature 1993, 365:113. 16. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ: Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994, 91:9770?774. 17. Lu M, Blacklow SC, Kim PS: A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995, 2:1075?082. 18. Lu M, Kim PS: A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn 1997, 15:465?71. 19. Delmedico M, Bray B, Cammack N, Davison D, Dwyer J, Frick L, Tvermoes N, Wring S, Zhang H, Greenberg M: Next generation HIV peptide fusion inhibitor candidates achieve potent, durable suppression of virus replication in vitro and improved pharmacokinetic properties. 13th Conference on Retroviruses and Opportunistic Infections 2006, Abstract No. 48. 20. Dwyer JJ, Wilson KL, Davison DK, Freel SA, Seedorff JE, Wring SA, Tvermoes NA, Matthews TJ, Greenberg ML, Delmedico MK: Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus. Proc Natl Acad Sci USA 2007, 104:12772?2777. 21. Liu Y, Zhao TJ, Yan YB, Zhou HM: Increase of soluble expression in Escherichia coli cytoplasm by a protein disulfide isomerase gene fusion system. Protein Expr Purif 2005, 44:155?61. 22. Lu L, Zhu Y, Diao J, Wang Z, Chen YH: V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory PubMed ID:http://www.ncbi.nlm.nih.gov/pubmed/27488460 CD8+ T cells. Vaccine 2008, 26:845?52. 23. Kutner RH, Zhang XY, Reiser J: Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors. Nat Protoc 2009, 4:495?05. 24. Ibegbu CC, Kennedy MS, Maddon PJ, Deen KC, Hicks D, Sweet RW, McDougal JS: Struc.